Eli Lilly, Type 2 diabetes

Eli Lilly's weight-loss drug helps nearly 99% of patients remain diabetes-free
Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of weekly injections.
Lilly unwraps detailed data showing tirzepatide kept nearly 99% of prediabetic patients diabetes-free over 3 years
Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drug | In the three-year SURMOUNT-1 trial,
Eli Lilly Say Most Tirzepatide Users Remained Diabetes-Free at 176 Weeks
Eli Lilly said new results from a Phase 3 study of its tirzepatide showed weekly injections in adults with pre-diabetes and obesity or overweight resulted in sustained weight loss, with nearly 99% remaining diabetes-free at 176 weeks.
Eli Lilly Gets Nod to Launch Weight-Loss Drug in Hong Kong - Bloomberg News
The drugmaker has received approval from the Hong Kong government to sell its tirzepatide injections — branded as Mounjaro — in a device called Kwikpen for both long-term weight management and type 2 diabetes, Eli Lilly told Bloomberg in a statement.
Zepbound Cuts the Risk of Progressing to Diabetes by 94%, Eli Lilly Data Shows
Nearly 99% of people with prediabetes and obesity or overweight who took weekly tirzepatide injections remained diabetes-free for over three years of using the drug, according to new data from the drugmaker Eli Lilly.
Lilly reports trial results of tirzepatide for treating obesity and pre-diabetes
Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating pre-diabetic and obese individuals. Spanning 176 weeks of treatment, the Phase III trial evaluated the efficacy and safety of tirzepatide in adults without type 2 diabetes (T2D) who were either obese or overweight with complications such as cardiovascular disease,
STAT24d
Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight
A turbulent series of events surrounding the supply of Eli Lilly’s blockbuster weight loss treatment has raised concerns around how the Food and Drug Administration maintains its list of ...
USA Today27d
Eli Lilly sues over knockoffs of signature weight loss drug, Zepbound
Pivotal Peptides says it offers research-grade tirzepatide ... from selling their versions of Eli Lilly's blockbuster weight loss and diabetes drugs. The agency said in a court filing it ...
CBS News25d
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Eli Lilly holds the patent for tirzepatide, and while the FDA doesn ... About 1 in 8 Americans have tried a GLP-1 drug for weight loss or diabetes, according to a Kaiser Family Foundation ...
Woman Dies After Using Weight-Loss Drug In U.K.’s First Case
A 58-year-old nurse from Scotland has died after taking two doses of weight-loss drug tirzepatide, also known as Mounjaro or ...
tyla5d
Company behind weight loss drug Mounjaro issues statement as first Brit dies after using jab twice
Company behind weight loss drug Mounjaro, Lilly, has issued an official statement after British woman, Susan McGowan, died ...
The UK thinks weight loss drugs could ease unemployment. Experts say that’s a fantasy
In the United Kingdom, the government is hoping weight loss drugs might improve public finances, eyeing their use to help ...
Reuters27d
Lilly sues online vendors, medical spa over copycat weight-loss drugs
Eli Lilly (LLY.N), opens new tab said on Monday it sued three medical spas and online vendors for selling products claiming to contain tirzepatide, the main ingredient in its popular ...
The Washington Post29d
Amid backlash, FDA changes course over shortage of weight-loss drugs
It also said it would not take enforcement action — for now — against pharmacies making their own versions of weight-loss drugs based on Eli Lilly’s tirzepatide, according to a letter it ...